University of Maryland School of Medicine and MRIGlobal in Collaboration Agreement - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
University of Maryland School of Medicine and MRIGlobal in Collaboration Agreement

Source: Company News Release

MRIGlobal and the University of Maryland School of Medicine today announced an intention to collaborate in the development of clinical specimen repositories, laboratory services for clinical trials, and research opportunities. The work will be performed under the collaboration agreement by MRIGlobal Dx, a division of MRIGlobal.

The non-exclusive memo of understanding has an initial two-year term, with annual renewals ongoing. Other terms of the agreement were not released.

With the agreement, the University of Maryland School of Medicine and MRIGlobal Dx plan to explore opportunities for procurement of clinical samples and patient specimen collection and banking.

Researchers in molecular and translational medicine use specimen repositories to develop new ways to diagnose, prevent, or treat diseases. Specimens may include fluids, tissues, tumors, cells and genetic material.

"This is a powerful agreement between two organizations committed to excellence and advancing knowledge," said Thomas M. Sack, Ph.D., President and Chief Executive Officer of MRIGlobal. "We are delighted to collaborate with the University of Maryland School of Medicine in bringing new diagnostic products and therapeutics to market."

University of Maryland School of Medicine Dean E. Albert Reece, who is Vice President for Medical Affairs at the University of Maryland and the John Z. and Akiko Bowers Distinguished Professor at the School of Medicine, commented: "As we continue to develop our resources as a top biomedical research institution, this agreement provides a critical service for our laboratories and clinical trials.

"We are excited to partner with a leading firm like MRIGlobal in this endeavor," he said.

For more information, visit www.mriglobaldx.com

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here